Friday 6 November 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.

Revenue: +36.3%
EPS: +36.0%
Free cash flow: +3.85%
Total debt: −26.6%

Quarter to September 2026, against a year earlier

907.91 5.01 +0.55%

Follow REGN

Alert me

Market cap: $93.4B
P/E: 19.2×
Fwd P/E: 19.2×
Dividend yield: 0.41%
F-score: 5/9
Altman Z: 7.49
Beneish M: −2.53
Dividend safety: 77/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

	Sep '26	Jun '26	Mar '26	Dec '25	Older periods
P/E ratio Full definition →	16.14	14.88	18.17	17.90	+8 more quarters Free account
P/S ratio Full definition →	4.56	4.13	5.39	5.63
P/FCF ratio Full definition →	21.26	17.93	21.20	21.44
P/Operating CF Full definition →	43.24	78.84	74.48	68.97
P/B ratio Full definition →	2.30	2.02	2.56	2.58
Price to Tangible BV Full definition →	2.40	2.11	2.67	2.69
EV/Sales Full definition →	4.22	3.84	5.03	5.32
EV/EBITDA Full definition →	13.26	13.63	18.01	18.52
EV/Operating CF Full definition →	14.71	12.73	14.98	15.33
EV/FCF Full definition →	19.65	16.67	19.81	20.27
Quick Ratio Full definition →	2.72	2.63	2.84	3.28
Current Ratio Full definition →	3.35	3.34	3.57	4.13
Net Debt/EBITDA Full definition →	(3.37)	(4.24)	(8.83)	(5.76)
Debt/Assets Full definition →	4.47%	4.76%	4.86%	6.67%
Debt/Equity Full definition →	0.06	0.06	0.06	0.09
Asset Turnover Full definition →	0.40	0.39	0.38	0.37
Operating CF/Net income Full definition →	0.92	0.63	1.48	1.39
Capex/Depreciation Full definition →	(2.95)	(2.35)	(2.27)	(2.00)
Interest Coverage Full definition →	193.23	117.59	49.84	72.12
Research and Development Expense of Revenue Full definition →	35.08%	38.03%	42.81%	41.86%
Selling, General and Administrative Expense of Revenue Full definition →	13.25%	15.43%	17.96%	19.95%
Intangible Assets out of Total Assets Full definition →	0.03	0.03	0.03	0.03
Share Based Compensation of Revenue Full definition →	5.00%	5.66%	7.14%	6.42%
Graham Net Nets Full definition →	0.13	0.13	0.11	0.11
Graham Number Full definition →	590.07	539.34	537.71	538.44
Earnings Yield Full definition →	6.20%	6.72%	5.50%	5.59%
Free Cash Flow Yield Full definition →	4.70%	5.58%	4.72%	4.66%
Revenue per Share Full definition →	50.30	41.74	34.67	37.13
Operating CF per Share Full definition →	17.54	7.91	10.37	11.19
Capex per Share Full definition →	(3.51)	(2.83)	(2.69)	(2.78)
Free Cash Flow per Share Full definition →	14.03	5.08	7.69	8.41
Cash per Share Full definition →	91.46	77.77	84.17	82.27
Shareholders Equity per Share Full definition →	329.39	308.48	302.15	298.82
Interest Debt per Share Full definition →	0.00	0.00	0.00	0.00
Book value per Share Full definition →	329.39	308.48	302.15	298.82
Free Cash Flow Full definition →	1,426.90	521.80	799.40	880.00
Working Capital Full definition →	14,593.00	12,915.40	13,101.50	13,653.50
Capital Expenditures Full definition →	(356.50)	(291.20)	(279.50)	(290.70)
Net Current Asset Value Full definition →	9,888.40	8,426.80	8,764.00	8,720.10
EV/EBIT Full definition →	14.66	15.51	20.69	21.34
Capex to Sales Full definition →	0.07	0.07	0.08	0.07
Price to Operating Income Full definition →	15.85	16.68	22.14	22.57
Other line items
Average Receivables Full definition →	6,632.85	6,087.70	5,646.00	5,976.50
Average Payables Full definition →	1,022.05	941.60	866.30	864.25
Average Inventory Full definition →	3,074.50	3,144.95	3,148.00	3,144.05
Average Assets Full definition →	42,287.30	39,974.90	39,207.00	39,159.05
Average Common Equity Full definition →	32,228.15	30,825.15	30,405.60	30,305.25

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026

Stockrow Weekly